symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NRXP,0.284,0.912893,1440870,23641269,0,0.221-1.54,-0.0102,"NRx Pharmaceuticals, Inc.",USD,0001719406,US0894821034,089482103,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.nrxpharma.com,"NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.",Mr. Stephen H. Willard Esq.,Healthcare,US,2,484 254 6134,1201 Orange Street,Wilmington,DE,19801,,24.2502,https://financialmodelingprep.com/image-stock/NRXP.png,2017-12-04,False,False,True,False,False
